5438
J. Am. Chem. Soc. 2000, 122, 5438-5442
Stability and Reactivity of Aryloxyl Radicals Derived from a Novel
Antioxidant BO-653 and Related Compounds. Effects of Substituent
and Side Chain in Solution and Membranes
Akira Watanabe,† Noriko Noguchi,† Akio Fujisawa,† Tatsuhiko Kodama,† Kunio Tamura,§
Osamu Cynshi,§ and Etsuo Niki*,†
Contribution from the Research Center for AdVanced Science and Technology, UniVersity of Tokyo,
4-6-1 Komaba, Tokyo 153-8904, Japan, and Fujigotemba Research Laboratories,
Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan
ReceiVed December 2, 1999
Abstract: 2,3-Dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran (BO-653) is a novel antioxidant
designed as a drug for inhibition of lipid peroxidation in vivo. To understand the dynamics of action of BO-
653 as an antioxidant, the effects of substituents and side chains on the stability and reactivity of the BO-653
derived radical were studied and compared with the aryloxyl radicals derived from related compounds including
R-tocopherol. The rate constants for the reactions of the aryloxyl radicals with themselves, lipid, hydroperoxide,
and ascorbate were measured with a stopped-flow electron spin resonance (ESR) spectroscope equipped with
a rapid mixing device. The ortho substituents exerted profound effects on the rate of bimolecular decay reactions
and the reaction with ascorbic acid, while the effects on the reactions with methyl linoleate and tert-butyl
hydroperoxide were much less significant. The side chain at the 2-position did not exert any effect in organic
solution but the two pentyl side chains, when compared with two methyl side chains, diminished the apparent
reactivities in the liposomal membranes.
Introduction
that the antioxidant suppresses atherosclerosis4,5 and the epi-
demiological studies suggest that high intake of vitamin E
reduces the risk of coronary heart disease.6 Probucol, 4,4′-
(isopropylidenedithio)bis(2,6-di-tert-butylphenol), is a synthetic
antiatherogenic drug used commercially, but it is known to have
the side effect of decreasing high-density lipoprotein in plasma.
BO-653, 2,3-dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butyl-
benzofran, is a novel antioxidant that has been designed,
synthesized, and found to exert a potent antioxidant activity
against lipid peroxidation7 and LDL oxidative modification in
vitro8,9 and also antiatherogenic activity in three different animal
models.5 Special attention has been paid in designing BO-653
to choose appropriate substituents and side chains which
determine the localization, retainment, and mobility within LDL
particle. The potency as an antioxidant is determined by many
factors as well as the chemical reactivity toward radicals.10 For
example, probucol is chemically much less reactive toward
The free radical-mediated autoxidation of organic compounds
by molecular oxygen is a double-edged sword and has both
positive and negative aspects. This is one of the key processes
in the present industrial chemistry and is applied for the
production of chemicals such as terephthalic acid and cyclo-
hexanol, important raw materials for synthetic polymers. On
the other hand, such oxidation also induces oxidative degradation
of plastics and rubbers and deterioration of foods and oils, and
therefore various antioxidants have been developed to inhibit
such oxidation. From the biological viewpoints, molecular
oxygen is essential to us for energy production, synthesis of
biologically active compounds, phagocytosis, and signal trans-
duction in vivo. At the same time, there is now increasing
experimental and clinical evidence which shows the involvement
of free radical-induced oxidative damage of lipids, proteins, and
DNA in a variety of pathological events, cancer, and aging.1
As a result, the role of antioxidants has received renewed
attention and both natural and synthetic antioxidants have been
extensively explored.2
(3) Steinberg, D.; Parthasarathy, S.; Carew, T. E.; Khoo, J. C.; Wiztum,
J. L. N. Engl. J. Med. 1989, 320, 915-924.
(4) (a) Kietchevsky, D.; Kirn, H. K.; Tepper, S. A. Proc. Soc. Exp. Biol.
Med. 1971, 136, 1216-1221. (b) Kita, T.; Nagano, Y.; Yokode, M.; Ishii,
K.; Kume, N.; Ooshima, A.; Yoshida, H.; Kawai, C. Proc. Natl. Acad. Sci.
U.S.A. 1987, 84, 5928-5831. (c) Carew, T. E.; Schwenke, D. C.; Steinberg,
D. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 7725-7729.
It is now generally accepted that oxidative modification of
low density lipoprotein (LDL) is a key initial event in the
progression of atherosclerosis which eventually causes coronary
heart disease and cerebral hemorrhage.3 The animal studies show
(5) Cynshi, O.; Kawabe, Y.; Suzuki, T.; Takashima, Y.; Kaise, H.;
Nakamura, M.; Ohba, Y.; Kato, Y.; Tamura, K.; Hayasaka, A.; Higashida,
A.; Sakaguchi, H.; Takeya, M.; Takahashi, K.; Inoue, K.; Noguchi, N.;
Niki, E.; Kodama T. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 10123-10128.
(6) Gey, K. F. BioFactors 1998, 7, 113-174.
† University of Tokyo.
§ Chugai Pharmaceutical Co., Ltd.
(1) (a) Sies, H., Ed. OxidatiVe Stress: Oxidants and Antioxidants;
Academic Press: London, 1991. (b) Halliwell, B.; Gutteridge, J. M. C.,
Eds. Free Radicals in Biology and Medicine, 3rd ed.; Oxford University
Press: Oxford, 1999.
(2) (a) Frei, B., Ed. Natural Antioxidants in Human Health and Disease;
Academic Press: San Diego, 1994, (b) Packer, L.; Cadenas, E., Eds.
Handbook of Synthetic Antioxidants; Marcel Dekker: New York, 1997.
(7) Noguchi, N.; Iwaki, Y.; Takahashi, M.; Komuro, E.; Kato, Y.;
Tamura, K.; Cynshi, O.; Kodama, T.; Niki, E. Arch. Biochem. Biophys.
1997, 342, 236-243.
(8) Noguchi, N.; Okimoto, Y.; Tsuchiya, J.; Cynshi, O.; Kodama, T.;
Niki, E. Arch. Biochem. Biophys. 1997, 347, 141-147.
(9) Mu¨ller, K.; Carpenter, K. L. H.; Freeman, M. A.; Mitchinson, M. J.
Free Rad. Res. 1999, 30, 59-71.
10.1021/ja9942080 CCC: $19.00 © 2000 American Chemical Society
Published on Web 05/23/2000